I've never heard of EquityGuru.com but no matter, I'm okay with some trumpets blasting or gazoos blowing.  

https://equity.guru/2020/02/05/resverlogix-rvx-t-sirona-biochem-sbm-v-sernova-sva-v-3-canadian-biotechs-tackle-330-billion-health-crisis/

For your consideration, here are three small cap Canadian Biotech companies developing solutions for diabetes patients.

Resverlogix (RVX.T) is a $278 million late-stage clinical biotechnology company that specialises in epigenetics.

Epigenetics involves changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.

In Q3 2019, Resverlogix completed a Phase 3 clinical trial – BETonMACE – with apabetalone for the treatment of high-risk cardiovascular disease patients, who also have type 2 diabetes mellitus and low levels of high-density lipoprotein.

Currently, these high-risk patients are administered drugs like Lipitor and Crestor. These status-quo drugs only prevent 30% of cardiovascular events within this patient group.

Resverlogix is focused on the remaining 70% of high-risk patients with cardiovascular disease and type 2 diabetes.

The primary objective is to determine if apabetalone increases time to the first occurrence of a Major Adverse Cardiac Event (MACE).

MACE is defined as a single composite endpoint of: 1) Cardiovascular death, or 2) Non-fatal myocardial infarction, or 3) Stroke.

10 clinical trials have been completed, there are 4 more anticipated trials to reach “Proof-of-concept”.